GlassScriptPhysician profile
Bhavana Pathak
NPI 1154610319
$731.07
in general payments reported to CMS, 2019-2025
14 companies · $24.44 in 2025
The $24.44 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2021: $289 · 2022: $161 · 2024: $34.93 · 2025: $24.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $140.53 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $121.61 | 2019 | |
| Alexion Pharmaceuticals, INC. | $99.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.86 | 2021 | |
| Puma Biotechnology, INC. | $64.37 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $58.14 | 2021-2024 | |
| Gilead Sciences, INC. | $38.14 | 2021-2024 | Trodelvy |
| Daiichi Sankyo INC. | $24.44 | 2025 | Enhertu |
| Amgen INC. | $22.52 | 2021 | |
| Incyte Corporation | $21.42 | 2021 | |
| Mylan Institutional INC. | $20.28 | 2021 | |
| Genzyme Corporation | $19.21 | 2021 | |
| Pfizer INC. | $17.68 | 2021 | |
| Seagen INC. | $16.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhavana Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.